Condition

Castration Levels of Testosterone

ClinicalTrials.gov condition label

Clinical trials19
Recruiting1
Common interventions25
Lead sponsors shown10

Clinical trials

19 shown
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · 2018-09-24
RECRUITING
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate CancerNCT03709550 · 2021-04-15
WITHDRAWN
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate CancerNCT03503344 · 2019-12-17
COMPLETED
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerNCT04159896 · 2019-11-13
TERMINATED
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT04033432 · 2019-09-20
UNKNOWN
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate CancerNCT03751436 · 2019-08-02
COMPLETED
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT03805594 · 2019-05-10
COMPLETED
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyNCT03442556 · 2018-08-24
TERMINATED
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate CancerNCT03406858 · 2018-06-07
COMPLETED
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT02966587 · 2018-05-15
WITHDRAWN
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelNCT03419234 · 2018-04-26
ACTIVE_NOT_RECRUITING
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate CancerNCT03456804 · 2018-03-08
COMPLETED
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT02703623 · 2016-05-18
ACTIVE_NOT_RECRUITING
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 PathwayNCT02598895 · 2016-01-26
COMPLETED
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerNCT02532114 · 2015-12-31
COMPLETED
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate CancerNCT02215161 · 2014-09-02
TERMINATED
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate CancerNCT01881867 · 2013-09-10
COMPLETED
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving EnzalutamideNCT02228265 · 2013-03-12
COMPLETED
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate CancerNCT01505868 · 2012-07-11
COMPLETED

Common interventions

Laboratory Biomarker AnalysisOTHER9CarboplatinDRUG4EnzalutamideDRUG4CabazitaxelDRUG3DocetaxelDRUG3PrednisoneDRUG3Abiraterone AcetateDRUG2ApalutamideDRUG2PembrolizumabBIOLOGICAL2AbirateroneDRUG1Androgen deprivation therapyDRUG1BicalutamideDRUG1Cytology Specimen Collection ProcedureOTHER1DecitabineDRUG1DegarelixDRUG1DurvalumabBIOLOGICAL1ESK981DRUG1FlutamideDRUG1Glycosylated Recombinant Human Interleukin-7BIOLOGICAL1Goserelin AcetateDRUG1HER2Bi-Armed Activated T CellsBIOLOGICAL1Histrelin AcetateDRUG1IpilimumabBIOLOGICAL1Leuprolide AcetateDRUG1Lutetium Lu 177-PSMA-617DRUG1

Trial status mix

COMPLETED10
TERMINATED3
ACTIVE_NOT_RECRUITING2
WITHDRAWN2
RECRUITING1
UNKNOWN1

Phase mix

PHASE214
PHASE15
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.